Loading market dashboard
Neurogene Inc.
NGNEHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company's common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducemen.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 financial results and highlighted recent corporate updates. “The significant unmet need in Rett syndrome and strong interest among physicians and caregivers continue to drive momentum for NGN-401, with approximately 90% of participants dosed in the Embolden™ registra.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting supporting the intracerebroventricular (ICV) route of administration as a routine approach for delivering medicines, including gene therapies, to treat central nervous system (CNS) disorders. The presentation furt.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 122,565 shares of the Company's common stock to two new employees (the “Inducement Grants”) on May 5, 2026 (the “Grant Date”), including an.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming poster presentation that will demystify the intracerebroventricular (ICV) route of administration as a well-established, routinely performed neurosurgical procedure and a deliberate delivery strategy designed to maximize efficacy for central nervous system (CNS) gene therap.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company's common stock to four new employees (the “Inducement Grants”) on April 6, 2026 (the “Grant Date”). The Inducem.
Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates. “We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than half of participants, and receipt of Breakthrough Therapy designation for NGN-40.
Neurogene (NASDAQ: NGNE) CEO and founder Rachel McMinn outlined the company's progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lead program McMinn described Neurogene as a genetic medicines company developing treatments for "devastating
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's webs.
